Cephalon Completes Acquisition of Ception Therapeutics

Apr 05 2010

FRAZER, Pennsylvania—Cephalon, Inc. (NASDAQ: CEPH) announced today that it has completed its previously announced acquisition of biotechnology company Ception Therapeutics, Inc. and that Ception is now a wholly-owned subsidiary of Cephalon.  Cephalon Chairman and CEO Frank Baldino Jr., Ph.D., said “We are fortunate to have the opportunity to advance CINQUIL(TM) (reslizumab) into Phase III studies for patients with eosinophilic ast ma. CINQUIL, in addition to our other biologics, peptides and small molecule compounds, provides Cephalon with a robust pipeline of opportunities to bring new therapies to patients over the next several years.”

Cephalon has six biologics in its pipeline focused on both inflammatory diseases and cancer. To view the full pipeline, please visit our website at http:/ / -science/pipeline.shtml

About Cephalon, Inc.
Cephalon is an international biopharmaceutical company dedicated to discovering, developing and bringing to market medications for difficult to treat and rare conditions. Since its inception in 1987, Cephalon has brought first-in-class and best- in-class medicines to patients around the world in several therapeutic areas. Cephalon has the distinction of being one of the
world’s fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 3,000 people worldwide. Cephalon has a growing presence in Europe, the Middle East and Africa.
The Cephalon European headquarters and pre-clinical development center are located in Maisons-Alfort, France, just outside of Paris. Key business units are located in England, Ireland, France, Germany, Italy, Spain, the Netherlands for the Benelux countries, and Poland for Eastern and Central European countries.  The company’s proprietary products in the United States include: NUVIGIL(R) (armodafinil) Tablets [C- IV], TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R) (cyclobenzaprine hydrochloride extended- release capsules), FENTORA(R) (fentanyl buccal tablet) [C- II], PROVIGIL(R) (modafinil) Tablets [C- IV], TRISENOX(R) (arsenic trioxide) injection, GABITRIL(R) (tiagabine hydrochloride), and ACTIQ(R) (oral transmucosal fentanyl citrate) [C- II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http:/ / or by calling 1-800-896-5855